Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
McKesson
Baxter
McKinsey
Medtronic
Merck
Colorcon
US Department of Justice
Fish and Richardson
Citi

Generated: February 19, 2018

DrugPatentWatch Database Preview

Valeant Pharms Company Profile

« Back to Dashboard

Summary for Valeant Pharms
International Patents:155
US Patents:34
Tradenames:38
Ingredients:34
NDAs:45

Drugs and US Patents for Valeant Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Valeant Pharms North APLENZIN bupropion hydrobromide TABLET, EXTENDED RELEASE;ORAL 022108-001 Apr 23, 2008 RX Yes No 7,671,094 ➤ Sign Up Y ➤ Sign Up
Valeant Pharms Llc MACUGEN pegaptanib sodium INJECTABLE;INTRAVITREAL 021756-001 Dec 17, 2004 RX Yes Yes ➤ Sign Up ➤ Sign Up
Valeant Pharms North APLENZIN bupropion hydrobromide TABLET, EXTENDED RELEASE;ORAL 022108-001 Apr 23, 2008 RX Yes No 7,241,805 ➤ Sign Up Y ➤ Sign Up
Valeant Pharms Intl UCERIS budesonide TABLET, EXTENDED RELEASE;ORAL 203634-001 Jan 14, 2013 RX Yes Yes 7,410,651 ➤ Sign Up Y ➤ Sign Up
Valeant Pharms ULTRAM ER tramadol hydrochloride TABLET, EXTENDED RELEASE;ORAL 021692-002 Sep 8, 2005 DISCN Yes No ➤ Sign Up ➤ Sign Up
Valeant Pharms North APLENZIN bupropion hydrobromide TABLET, EXTENDED RELEASE;ORAL 022108-002 Apr 23, 2008 RX Yes No 7,572,935 ➤ Sign Up Y ➤ Sign Up
Valeant Pharms North TIAZAC diltiazem hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 020401-002 Sep 11, 1995 AB4 RX Yes No ➤ Sign Up ➤ Sign Up
Valeant Pharms North ANDROID 10 methyltestosterone TABLET;ORAL 086450-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Sign Up ➤ Sign Up
Valeant Pharms Intl GIAZO balsalazide disodium TABLET;ORAL 022205-001 Feb 3, 2012 AB RX Yes Yes 7,625,884 ➤ Sign Up ➤ Sign Up
Valeant Pharms Intl APRISO mesalamine CAPSULE, EXTENDED RELEASE;ORAL 022301-001 Oct 31, 2008 RX Yes Yes 8,940,328 ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Valeant Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Valeant Pharms North VASOTEC enalapril maleate TABLET;ORAL 018998-001 Dec 24, 1985 4,374,829*PED ➤ Sign Up
Valeant Pharms Llc TASMAR tolcapone TABLET;ORAL 020697-001 Jan 29, 1998 5,236,952 ➤ Sign Up
Valeant Pharms North IPRIVASK desirudin recombinant INJECTABLE;SUBCUTANEOUS 021271-001 Apr 4, 2003 5,733,874 ➤ Sign Up
Valeant Pharms North VASOTEC enalapril maleate TABLET;ORAL 018998-003 Dec 24, 1985 4,374,829*PED ➤ Sign Up
Valeant Pharms Llc LIBRIUM chlordiazepoxide hydrochloride INJECTABLE;INJECTION 012301-001 Approved Prior to Jan 1, 1982 4,316,897 ➤ Sign Up
Valeant Pharms Llc MACUGEN pegaptanib sodium INJECTABLE;INTRAVITREAL 021756-001 Dec 17, 2004 6,051,698 ➤ Sign Up
Valeant Pharms MAXAIR pirbuterol acetate AEROSOL, METERED;INHALATION 019009-001 Dec 30, 1986 3,700,681 ➤ Sign Up
Valeant Pharms North RENOVA tretinoin CREAM;TOPICAL 021108-001 Aug 31, 2000 4,603,146 ➤ Sign Up
Valeant Pharms LIBRAX chlordiazepoxide hydrochloride; clidinium bromide CAPSULE;ORAL 012750-001 Approved Prior to Jan 1, 1982 4,316,897 ➤ Sign Up
Valeant Pharms ULTRAM ER tramadol hydrochloride TABLET, EXTENDED RELEASE;ORAL 021692-003 Sep 8, 2005 6,254,887 ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for VALEANT PHARMS drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Tablets 1.1 g ➤ Subscribe 11/5/2013
➤ Subscribe Extended-release Tablets 9 mg ➤ Subscribe 3/11/2013
➤ Subscribe Extended-release Capsules 0.375 g ➤ Subscribe 4/3/2012
➤ Subscribe Cream 0.5% ➤ Subscribe 7/29/2011
➤ Subscribe Extended-release Tablets 522 mg ➤ Subscribe 12/24/2009
➤ Subscribe Extended-release Tablets 174 mg ➤ Subscribe 9/28/2009
➤ Subscribe Extended-release Tablets 348 mg ➤ Subscribe 9/24/2009
➤ Subscribe Rectal Gel 5 mg/mL, 2mL pre-filled syringe ➤ Subscribe 12/23/2008
➤ Subscribe Rectal Gel 5 mg/mL, 4mL pre-filled syringe ➤ Subscribe 12/8/2008
➤ Subscribe Extended-release Tablets 300 mg ➤ Subscribe 9/25/2007
➤ Subscribe Extended-release Tablets 200 mg ➤ Subscribe 3/28/2007
➤ Subscribe Extended-release Tablets 100 mg ➤ Subscribe 1/8/2007
➤ Subscribe Rectal Gel 2.5 mg/0.5 mL, 5 mg/mL, 10 mg/2 mL, 15 mg/3 mL and 20 mg/4 mL ➤ Subscribe 3/23/2004
Premature patent expirations for VALEANT PHARMS

Expiration due to failure to pay maintenance fee

Patent Number Expiration Date
➤ Sign Up ➤ Sign Up

Non-Orange Book US Patents for Valeant Pharms

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,592,203 Controlled release and taste masking oral pharmaceutical composition ➤ Sign Up
6,277,412 Pellet-type formulation intended for treating the intestinal tract ➤ Sign Up
7,563,823 Modified release formulations of a bupropion salt ➤ Sign Up
8,354,453 Bupropion hydrobromide and therapeutic applications ➤ Sign Up
8,029,823 Controlled release and taste masking oral pharmaceutical composition ➤ Sign Up
7,569,611 Modified release formulations of a bupropion salt ➤ Sign Up
7,645,901 Modified release formulations of a bupropion salt ➤ Sign Up
8,932,628 Modified release formulations of a bupropion salt ➤ Sign Up
7,884,136 Modified-release formulations of a bupropion salt ➤ Sign Up
7,579,380 Modified release formulations of a bupropion salt ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for Valeant Pharms Drugs

Supplementary Protection Certificates for Valeant Pharms Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2000 00018 Denmark ➤ Sign Up PRODUCT NAME: BUPROPIONHYDROCHLORID; NAT. REG. NO/DATE: 31347 20000606; FIRST REG. NO/DATE: NL 24160 19991201
C0114 Belgium ➤ Sign Up PRODUCT NAME: DESIRUDIN; REGISTRATION NO/DATE: EU/1/97/043/001 19970709
C/GB06/021 United Kingdom ➤ Sign Up PRODUCT NAME: PEGAPTANIB, PREFERABLY IN THE FORM OF ITS SODIUM SALT; REGISTERED: UK EU/1/05/325/001 20060201
401 Luxembourg ➤ Sign Up PRODUCT NAME: CLINDAMYCINE(EN TANT QUE PHOPSHATE DE CLINDAMYCINE)ET TRETINOINE
C0013 Belgium ➤ Sign Up PRODUCT NAME: TIMOLOLI MALEAS EQ. TIMOLOLUM; NATIONAL REGISTRATION/DATE: 922 IS 166 F 13 19950627; FIRST REGISTRATION: SE 11901 19930910
/1999 Austria ➤ Sign Up PRODUCT NAME: DORZOLAMID ODER EIN OPHTHALMOLOGISCH ANNEHMBARES SALZ DAVON, VORZUGSWEISE DORZOLAMIDHYDROCHLORID, UND TIMOLOL ODER EIN OPHTHALMOLOGISCH ANNEHMBARES SALZ DAVON, VORZUGSWEISE TIMOLOLMALEAT; NAT. REGISTRATION NO/DATE: 1-22701, 1-22702 19980828; FIRST REGISTRATION: DK 9794 19980306
2013025,C1304992 Lithuania ➤ Sign Up PRODUCT NAME: CLINDAMYCINUM + TRETINOINUM; REGISTRATION NO/DATE: LT/1/13/3279/001, 2013 04 26 LT/1/13/3279/002, 2013 04 26 PA1332/043/001 20130323
/1997 Austria ➤ Sign Up PRODUCT NAME: TOLCAPONE; REGISTRATION NO/DATE: EU/1/97/044/001 - EU/1/97/044/006 19970827
2006004 Lithuania ➤ Sign Up PRODUCT NAME: PEGAPTANIBUM; REG. NO/DATE: EU/1/05/325/001 20060131
00617 Netherlands ➤ Sign Up PRODUCT NAME: COMBINATIE VAN CLINDAMYCINE, DESGEWENST IN DE VORM VAN CLINDAMYCINEFOSFAAT EN TRETINOINE; NAT. REGISTRATION NO/DATE: RVG 109745 20130626; FIRST REGISTRATION: PA1332/043/001 20130322
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
Julphar
McKinsey
Cipla
Queensland Health
Fuji
McKesson
UBS
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot